MeiraGTx Holdings plc Ordinary Shares (MGTX) is a publicly traded Healthcare sector company. As of May 21, 2026, MGTX trades at $9.58 with a market cap of $870.53M and a P/E ratio of -6.41. MGTX moved +4.71% today. Year to date, MGTX is +26.89%; over the trailing twelve months it is +74.18%. Its 52-week range spans $3.97 to $11.85. Analyst consensus is strong buy with an average price target of $24.00. Rallies surfaces MGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MeiraGTx Reports FDA Breakthrough, Raises $100M, Acquires Bota-vec for $25M: MeiraGTx secured a Breakthrough Therapy Designation for its AAV2-hAQP1 salivary gland gene therapy and reported positive three-year Phase 1 AQUAx data confirming sustained salivary flow improvements in radiation-induced xerostomia patients. The company acquired full rights to bota-vec for X-linked retinitis pigmentosa from J&J with $25 million upfront and raised $100 million in financing.
| Metric | Value |
|---|---|
| Price | $9.58 |
| Market Cap | $870.53M |
| P/E Ratio | -6.41 |
| EPS | $-1.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.85 |
| 52-Week Low | $3.97 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $79.76M |
| Net Income | $-120.53M |
| Gross Margin | 0.00% |
6 analysts cover MGTX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.00.